Nephrology focuses on diagnosing and treating kidney diseases. The kidneys filter waste, balance fluids, regulate blood pressure, and manage acute and chronic conditions.
Send us all your questions or requests, and our expert team will assist you.
Treating Fabry nephropathy is a twofold battle. First, doctors aim to treat the underlying root cause: the missing enzyme. By replacing or enhancing the enzyme, they can clear the fatty buildup causing the damage. Second, they treat the kidneys directly using standard protective measures to stop protein leakage and manage blood pressure. This combination approach offers the best chance of stabilizing kidney function and preventing failure.
The treatment landscape for Fabry disease has evolved significantly in recent years. What was once a condition with no specific therapy now has multiple options. However, treatment is a lifelong commitment. It requires regular infusions or daily pills, along with consistent monitoring. This section outlines the specific therapies available and the routine follow-up care necessary to stay healthy.
Enzyme Replacement Therapy, or ERT, is the cornerstone of treatment for Fabry disease. It involves giving the patient a synthetic version of the missing alpha-galactosidase A enzyme. This is delivered directly into the bloodstream through an intravenous (IV) infusion.
The synthetic enzyme travels through the blood and is taken up by the cells, including the kidneys. Once inside, it gets to work breaking down the accumulated GL-3 fat. It essentially functions as the missing cleaning crew. Regular infusions help clear the stored waste and prevent new buildup. This process can stabilize kidney function, reduce pain, and improve heart health.
ERT is typically given every two weeks. The infusion takes a few hours. Initially, this process is done at a hospital or infusion center to monitor for allergic reactions. Once the patient tolerates it well, many can transition to home infusions, where a nurse comes to the house, making the treatment much more convenient. It is a long-term therapy; stopping it usually causes the fatty buildup to return.
For some patients, there is an oral alternative called chaperone therapy. This is a pill taken every other day. It works differently than ERT. It is designed for patients who produce an enzyme that is misshapen and unstable.
The chaperone molecule acts like a scaffold or a brace. It binds to the patient’s unstable enzyme, stabilizing it so it can reach the lysosome and work. It “rescues” the body’s natural enzyme activity. However, this drug only works for patients with specific “amenable” gene mutations. A genetic test is required to see if a patient qualifies. For those who do, it offers freedom from needles and hospital visits.
Regardless of whether a patient is on specific Fabry treatment, standard kidney protection is mandatory. The most important medications are ACE inhibitors (like lisinopril) or ARBs (like losartan). These are blood pressure pills, but they do much more than lower pressure.
These drugs lower the pressure inside the kidney’s filters. This reduces the mechanical stress on the delicate tissues and significantly lowers proteinuria (protein leakage). By stopping the protein leak, these drugs slow down the scarring process. They are prescribed even if the patient has normal blood pressure, specifically for their kidney-shielding effects.
Treatment also focuses on quality of life. The burning nerve pain (acroparesthesia) is often treated with medications like gabapentin or carbamazepine, which stabilize nerve firing. These are not standard painkillers but nerve-calming drugs.
For digestive issues, patients might need smaller meals or medication to help the stomach empty. For those who cannot sweat, avoiding overheating and staying hydrated is crucial. Depression and anxiety are also addressed as part of the holistic care plan, recognizing the mental toll of a chronic disease.
Once treatment starts, the journey isn’t over. Regular monitoring is essential to ensure the treatment is working. Patients typically see their nephrologist and Fabry specialist every 6 to 12 months.
Doctors monitor a specific biomarker in the blood called lyso-Gb3. This is a breakdown product of the fatty substance. Ideally, treatment should cause lyso-Gb3 levels to drop and stay low. If levels rise, it might mean the body is developing antibodies against the ERT, reducing its effectiveness.
Kidney function (eGFR) and urine protein are checked at every visit. Cardiac MRIs and echocardiograms are done regularly to check heart thickness. If kidney function continues to decline despite treatment, the team might discuss preparing for dialysis or kidney transplant. However, with early and effective treatment, the goal is to never reach that stage.
Send us all your questions or requests, and our expert team will assist you.
Yes, currently, Fabry disease requires lifelong treatment to prevent the fatty buildup from returning. Gene therapy is being researched as a potential one-time cure, but it is not yet standard.
Only if you have an “amenable mutation.” About 35–50% of patients have mutations that respond to the pill. Your doctor can check your genetic report to tell you.
Treatment cannot remove scar tissue that has already formed. It is best at stabilizing the kidneys and preventing new damage. This is why starting early is so important.
Some patients develop infusion reactions like fever or chills, but these are manageable. Over time, some develop antibodies that might make the drug less effective, which doctors monitor for.
Yes. Kidney transplant is a very successful option for Fabry patients who reach kidney failure. The new kidney will have normal enzyme activity and will not develop Fabry nephropathy.
Your Comparison List (you must select at least 2 packages)
